← Leaderboards
Morris Schambelan
University Of California San Francisco
$4,926,809
Attributed
$4,926,809
Total exposure
21
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $440K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,926,809 · 21
By mechanism
R01$3,286,303 · 4
R21$1,081,743 · 2
M01$542,600 · 13
P41$16,163 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Aditi Bhargava$3,649,255
- Kathleen Mulligan$3,973,439
- Robert B Jaffe$18,036,743
- Kirsten L Johansen$9,035,881
- Elissa S. Epel$23,864,091
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsCachexiaHuman Therapy EvaluationAidsAids TherapyBody CompositionSomatotropinBioenergeticsHormone TherapyThalidomideDrug Screening /EvaluationMetabolism DisorderHormone Regulation /Control MechanismCarbohydrate MetabolismLipid MetabolismBody WeightElectrolyte BalanceCombination ChemotherapyProtein MetabolismLongitudinal Human StudyNitrogen BalanceOutcomes Research
Grant awards (60)
DEVELOPMENT OF APPROPRIATE CORONARY HEART DISEASE RISK PREDICTION MODELS$12,323
P41 · FY2010 · RR · contact PI
DEVELOPMENT OF APPROPRIATE CORONARY HEART DISEASE RISK PREDICTION MODELS$3,840
P41 · FY2009 · RR · contact PI
Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV$180,205
R21 · FY2008 · AT · contact PI
Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV$220,660
R21 · FY2007 · AT · contact PI
Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV$189,375
R21 · FY2006 · AT · contact PI
Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV$37,003
R21 · FY2006 · AT · contact PI
Can IGF-I/IGFBP-3 Reverse Central Fat Accumulation?$227,250
R21 · FY2005 · DK
RECOMBINANT HUMAN LEPTIN TREATMENT OF PATIENTS W/ HIV-ASSOCIATED LIPODYSTROPHY$147,062
M01 · FY2005 · RR
EFFECTS OF IGF-1/IGFBP-3 IN HIV INFECTED PATIENTS WITH FAT ACCUMULATION$31,838
M01 · FY2005 · RR
MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATING HEPATIC LIPID CONSENT$22,741
M01 · FY2005 · RR
ERGOGENIC EFFECTS OF CREATINE SUPPLEMENTATION$8,339
M01 · FY2005 · RR
HYPERTENSIVE, FLUID, ELECTROLYTE AND ACID-BASE DISORDERS$2,773
M01 · FY2005 · RR
Leptin Treatment of HIV-Associated Lipodystrophy$371,320
R01 · FY2004 · DK
Can IGF-I /IGFBP-3 Reverse Central Fat Accumulation?$227,250
R21 · FY2004 · DK
Recombinant human leptin treatment of patients w/ HIV-associated lipodystrophy$175,110
M01 · FY2004 · RR
Ergogenic effects of creatine supplementation$144,835
M01 · FY2004 · RR
MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATING HEPATIC LIPID CONSENT$3,329
M01 · FY2004 · RR
Hypertensive, fluid, electrolyte and acid-base disorders$2,061
M01 · FY2004 · RR
Leptin Treatment of HIV-Associated Lipodystrophy$371,536
R01 · FY2003 · DK
Leptin Treatment of HIV-Associated Lipodystrophy$369,776
R01 · FY2002 · DK
Ergogenic Effects of Creatine Supp .in HIV-Assoc.Wasting$258,981
R01 · FY2002 · AT
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECTS IN AIDS$237,410
R01 · FY2002 · DK
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$0
M01 · FY2002 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$0
M01 · FY2002 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$0
M01 · FY2002 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$0
M01 · FY2002 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$0
M01 · FY2002 · RR
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$0
M01 · FY2002 · RR
ENDOCRINE ASPECTS OF HIV INFECTION$0
M01 · FY2002 · RR
ENDOCRINE ASPECTS OF HIV INFECTION$0
M01 · FY2002 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$0
M01 · FY2002 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$0
M01 · FY2002 · RR
Ergogenic Effects of Creatine Supp .in HIV-Assoc.Wasting$246,604
R01 · FY2001 · AT
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECTS IN AIDS$237,444
R01 · FY2001 · DK
ENDOCRINE ASPECTS OF HIV INFECTION$0
M01 · FY2001 · RR
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$0
M01 · FY2001 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$0
M01 · FY2001 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$0
M01 · FY2001 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$0
M01 · FY2001 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$672,717
R01 · FY2000 · DK
Ergogenic Effects of Creatine Supp .in HIV-Assoc.Wasting$282,755
R01 · FY2000 · AT
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECTS IN AIDS$237,760
R01 · FY2000 · DK
MULTICENTER STUDY OF RH GROWTH HORMONE IN AIDS ASSOCIATED CATABOLISM/WEIGHT LOSS$564
M01 · FY2000 · RR
ANABOLIC THERAPY IN DEBILITATED DIALYSIS PATIENTS$564
M01 · FY2000 · RR
TRIAL OF RECOMBINANT HUMAN GROWTH HORMONE IN TREATMENT OF HIV ASSOCIATED WASTING$564
M01 · FY2000 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$564
M01 · FY2000 · RR
ENDOCRINE ASPECTS OF HIV INFECTION$564
M01 · FY2000 · RR
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$564
M01 · FY2000 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$564
M01 · FY2000 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$564
M01 · FY2000 · RR
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$0
M01 · FY2000 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$0
M01 · FY2000 · RR
MITIGATION OF EPISODIC WASTING IN HIV INFECTION$0
M01 · FY2000 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$0
M01 · FY2000 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$0
M01 · FY2000 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV INDUCED WASTING$0
M01 · FY2000 · RR
ANABOLIC THERAPIES AND THEIR METABOLIC EFFECT IN AIDS$0
M01 · FY2000 · RR
ENDOCRINE ASPECTS OF HIV INFECTION$0
M01 · FY2000 · RR
ENDOCRINE ASPECTS OF HIV INFECTION$0
M01 · FY2000 · RR
ACTG313--MEGESTROL ACETATE PLUS TESTOSTERONE ENANTHATE PLACEBO IN HIV WASTING$0
M01 · FY2000 · RR